Please assess the completion status of the following clinical trial:

Trial Title: Combination Chemotherapy Followed by Bone Marrow and/or Peripheral Stem Cell Transplantation in Treating Patients With Recurrent Medulloblastoma or CNS Germ Cell Tumors

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of recurrent medulloblastoma or CNS germ cell tumor~  * Histologic review of the primary intracranial or spinal cord tumor required~    * Biopsy and reduction of tumor bulk prior to study encouraged but not required~* No more than 1 prior primary therapy (radiotherapy or chemoradiotherapy) and/or 1 prior salvage therapy~  * Patients with progression on salvage therapy ineligible~* Minimal residual disease (tumor bulk no more than 1.5 cm) or in second clinical complete remission (CR)~* Bone marrow infiltration with or without mass lesions or isolated abnormal CSF cytology as the only manifestation of recurrent disease allowed if a clinical CR is first achieved with conventional therapy~PATIENT CHARACTERISTICS:~Age:~* 2 to 25~Performance status:~* Karnofsky 80-100%~Life expectancy:~* More than 8 weeks~Hematopoietic:~* Absolute neutrophil count greater than 1,000/mm\^3~* Platelet count greater than 100,000/mm\^3~Hepatic:~* Bilirubin less than 1.5 mg/dL~* SGPT less than 80 IU~Renal:~* Creatinine less than 1.2 mg/dL~Cardiovascular:~* LVEF normal~Other:~* No infection~* Able to tolerate vigorous hydration~* Not pregnant~* Fertile patients must use effective contraception~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* Not specified~Chemotherapy:~* See Disease Characteristics~* Prior cyclophosphamide or ifosfamide allowed~Endocrine therapy:~* No concurrent dexamethasone as an antiemetic~* Other concurrent corticosteroids allowed~Radiotherapy:~* See Disease Characteristics~* Pretransplantation radiotherapy boost allowed~Surgery:~* See Disease Characteristics~* Pretransplantation surgery allowed~Other:~* At least 4 weeks since prior therapy except corticosteroids

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 25 Years
- Healthy Volunteers: f

Study Arms:
- Ablative chemo followed by autologous bone marrow (ABM) rescue (Type: EXPERIMENTAL): Autologous bone marrow and/or peripheral blood stem cells (PBSC) are harvested. Patients then receive intensive cyclophosphamide IV over 1 hour on days -8 to -5 and melphalan IV over 15 minutes on days -4 to -2. Bone marrow is reinfused on day 0. PBSC are reinfused on day 0 if used alone or on day 1 if used after autologous bone marrow transplantation (ABMT). Sargramostim (GM-CSF) is administered IV over 2 hours daily beginning 4 hours after ABMT and continuing until blood counts recover.

Based on this trial design, predict the completion outcome and termination type (if applicable).